The Zhitong Finance App learned that Siludi Pharmaceutical Co., Ltd. (01244) soared rapidly in early trading. At one point, the increase was close to 130%. As of press release, it had risen 51.38% to HK$3.3 million, with a turnover of HK$7.339 million.

According to the news, on August 19, Moderna and MSD announced that the new tumor antigen mRNA vaccine mRNA-4157+K drug combined with adjuvant treatment of melanoma had reached the primary endpoint RFS and DMFS as a key secondary endpoint. This milestone verified the commercialization potential of mRNA technology in the field of oncology treatment, directly detonating the global pharmaceutical sector.

According to public information, Siludi Pharmaceuticals has been on the cancer circuit for a long time. From the world's first subcutaneous PDL1 injection to the world's first WT1 tumor vaccine, self-built LNP delivery systems and AI-tumor vaccine screening platforms, In-vivo Car T/NK, etc. all aim at the cutting edge of the world and resonate with the world's top tumor immunity racetracks. As global cancer immunotherapy enters a new era of gene therapy, Siludi Pharmaceutical is expected to continue to be a catalyst for revaluation with its differentiated pipeline layout and commercialization pace.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.